These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21691580)

  • 1. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm.
    Park J; Lee MS; Harrison AR
    Clin Ophthalmol; 2011; 5():725-32. PubMed ID: 21691580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.
    Jimenez-Shahed J
    Neuropsychiatr Dis Treat; 2012; 8():13-25. PubMed ID: 22275842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
    Mitsikostas DD; Dekundy A; Hanschmann A; Althaus M; Scheschonka A; Pagan F; Jankovic J
    Curr Med Res Opin; 2021 Oct; 37(10):1761-1768. PubMed ID: 34384301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
    Frevert J
    Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
    Saad J; Gourdeau A
    J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins.
    Dressler D
    Eur J Neurol; 2012 Mar; 19(3):385-9. PubMed ID: 22035051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines.
    Prager W
    Clin Pharmacol; 2013; 5():39-52. PubMed ID: 23516136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
    Jankovic J
    Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.
    Jost WH; Benecke R; Hauschke D; Jankovic J; Kaňovský P; Roggenkämper P; Simpson DM; Comella CL
    Drug Des Devel Ther; 2015; 9():1913-26. PubMed ID: 25897202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xeomin in the treatment of cervical dystonia.
    Benecke R
    Eur J Neurol; 2009 Dec; 16 Suppl 2():6-10. PubMed ID: 20002740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
    Jost WH; Blümel J; Grafe S
    Drugs; 2007; 67(5):669-83. PubMed ID: 17385940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tear osmolarity, dry eye syndrome, blepharospasm and botulinum neurotoxin.
    Girard B; de Saint Sauveur G
    J Fr Ophtalmol; 2021 Dec; 44(10):1553-1559. PubMed ID: 34756743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
    Truong DD; Gollomp SM; Jankovic J; LeWitt PA; Marx M; Hanschmann A; Fernandez HH;
    J Neural Transm (Vienna); 2013 Sep; 120(9):1345-53. PubMed ID: 23435927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
    Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
    J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xeomin is free from complexing proteins.
    Frevert J
    Toxicon; 2009 Oct; 54(5):697-701. PubMed ID: 19292989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)).
    Dressler D; Tacik P; Adib Saberi F
    J Neural Transm (Vienna); 2014 Jan; 121(1):29-31. PubMed ID: 23913131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xeomin
    Mastrorilli V; De Angelis F; Vacca V; Pavone F; Luvisetto S; Marinelli S
    Toxins (Basel); 2023 Mar; 15(4):. PubMed ID: 37104185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.